Conference Correspondent

Conference Correspondent

informCLL registry analysis revealed that prognostic testing patterns in the real-world setting remain suboptimal despite inclusion in National Comprehensive Cancer Network and International Workshop on Chronic Lymphocytic Leukemia guidelines.
Researchers evaluating the Bruton’s tyrosine kinase inhibitor acalabrutinib monotherapy in relapsed/refractory and high-risk, treatment-naïve chronic lymphocytic leukemia (CLL) patients reported high response rates and an acceptable safety profile.
Although ibrutinib is generally cost-effective in first-line use compared with chemotherapy and chemoimmunotherapy, a subset of ibrutinib-treated patients with cardiovascular events had a mitigating impact on the total cost of care.
In a phase 3 study, the combination of ibrutinib and rituximab provided superior progression-free survival and overall survival relative to the combination of fludarabine, cyclophosphamide, and rituximab for younger patients with previously untreated chronic lymphocytic leukemia (CLL)
This phase 3 follow-up analysis evaluates the efficacy and safety of ibrutinib, alone and in combination with rituximab, in patients with Waldenström’s macroglobulinemia.
In an ex vivo analysis, the combination of venetoclax and ibrutinib showed encouraging biologic activity in several leukemia subtypes, including acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.
Using a national claims database, researchers found that previously untreated patients receiving chemoimmunotherapy had a higher total cost of care compared with patients receiving single-agent ibrutinib.
New data suggest that adding obinutuzumab to ibrutinib in patients with chronic lymphocytic leukemia (CLL) may be effective at improving minimal residual disease (MRD) response rates, especially in patients with low tumor burden after prior ibrutinib therapy.
Researchers report promising findings for patients treated with a venetoclax-rituximab combination regimen in relapsed/refractory chronic lymphocytic leukemia (CLL).
An interim analysis from the informCLL Real-World Registry found that most ibrutinib-treated patients started at the FDA-recommended once-daily dose of 420 mg, with few dose interruptions or reductions over time.
Page 1 of 16
Results 1 - 10 of 153
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME